SS Innovations International (NASDAQ: SSII) has reported a 79% increase in cumulative procedures performed with its SSi Mantra surgical robotic system, reaching 14,103 as of September 8, 2026, up from 7,885 at the end of 2025. The installed base of systems grew 42% to 238 units, now deployed across 12 countries. Approximately 1,500 physicians have been trained on the platform, which has been used for more than 170 types of surgical procedures. Recent international milestones include the launch of robotic cardiac surgery in Colombia, the first SSi Mantra installation in Sri Lanka, and the first telesurgery within the Philippines. The company also highlighted 258 cumulative pediatric robotic surgeries and 188 robotic telesurgeries as of August 31, including a telesurgery spanning over 13,600 miles between Colombia and India. In August, five SSi Mantra systems were used to complete 50 robotic general surgery procedures in a single day in India.
These developments underscore the rapid adoption of the SSi Mantra platform and its expanding global footprint. The significant growth in procedures and installations demonstrates increasing trust among surgeons and healthcare institutions, particularly in emerging markets where access to advanced surgical technology has been limited. The system’s versatility, with over 170 procedure types, positions it as a comprehensive solution for a wide range of surgical needs. The focus on telesurgery and pediatric applications further highlights its potential to address unmet needs in remote and specialized care. The milestone of 50 procedures in a single day using five systems in India illustrates the efficiency and scalability of the technology, which could lead to improved patient outcomes and reduced waiting times.
Looking ahead, SS Innovations expects the U.S. Food and Drug Administration to complete its review of the SSi Mantra 510(k) premarket notification by the end of the first quarter of 2027 and believes European Union CE marking certification can be obtained by year-end 2026. These regulatory milestones are critical for the company’s expansion into high-value markets. FDA clearance would allow SS Innovations to compete directly in the United States, the world’s largest market for surgical robotics, while CE marking would enable sales across the European Union. Success in these endeavors could significantly accelerate revenue growth and enhance the company’s global competitive position. The company’s vision to make robotic surgery affordable and accessible aligns with the growing demand for cost-effective healthcare solutions worldwide.
SS Innovations International, Inc. develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.
For more details, view the full report at https://ibn.fm/DJILj. The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer.
